Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31643871 | 0.77 | CYP3A4 (0.63) | CYP3A4HPGDKMT2ASMN1; SMN2POLB | |
| SCHEMBL11067587 | 0.74 | CYP3A4 (0.79) | CYP3A4HPGDKDM4EKMT2APOLB | |
| SCHEMBL12565531 | 0.71 | ALDH1A1 (0.45) | CYP3A4HPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL10662864 | 0.71 | HPGD (0.55) | CYP3A4HPGDKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL31395140 | 0.71 | KDM4E (0.48) | HPGDHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14097986 | 0.70 | HDAC3 (0.44) | CYP3A4HPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL19407746 | 0.70 | HDAC3 (0.48) | HPGDHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5313651 | 0.69 | CYP3A4 (0.69) | CYP3A4HPGDKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL950536 | 0.69 | CYP3A4 (1.00) | CYP3A4HPGDKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2027170 | 0.69 | CYP3A4 (0.69) | CYP3A4HPGDKDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | LIFEMINE THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137071-A2 | TRIESTER COMPOUNDS AND METHODS OF USE THEREOF | LIFEMINE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | CYP46A1, CYP17A1, CYP27A1 | CYP3A4 104/4885HPGD 815/4885HDAC3 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.